Cargando…

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials

The extremely rapid spread of the SARS-CoV-2 has already resulted in more than 1 million reported deaths of coronavirus disease 2019 (COVID-19). The ability of infectious particles to persist on environmental surfaces is potentially considered a factor for viral spreading. Therefore, limiting viral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Criscuolo, Elena, Diotti, Roberta A., Ferrarese, Roberto, Alippi, Cesare, Viscardi, Gabriele, Signorelli, Carlo, Mancini, Nicasio, Clementi, Massimo, Clementi, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872580/ https://www.ncbi.nlm.nih.gov/pubmed/33399524 http://dx.doi.org/10.1080/22221751.2021.1872354

Ejemplares similares

Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2
por: Criscuolo, Elena, et al.
Publicado: (2022)

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
por: Clementi, Nicola, et al.
Publicado: (2020)

JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
por: Diotti, Roberta Antonia, et al.
Publicado: (2013)

Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape?
por: Nicasio, Mancini, et al.
Publicado: (2012)

Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy
por: Castelli, Matteo, et al.
Publicado: (2021)

HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role
por: Sautto, Giuseppe, et al.
Publicado: (2012)

Influenza B-cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines
por: Clementi, Nicola, et al.
Publicado: (2012)

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
por: Caputo, Valeria, et al.
Publicado: (2020)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes
por: Mancini, Nicasio, et al.
Publicado: (2009)

Viral Respiratory Pathogens and Lung Injury
por: Clementi, Nicola, et al.
Publicado: (2021)

A Biologically-validated HCV E1E2 Heterodimer Structural Model
por: Castelli, Matteo, et al.
Publicado: (2017)

Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
por: Severa, Martina, et al.
Publicado: (2021)

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens
por: Clementi, Nicola, et al.
Publicado: (2012)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Molecular Signatures of Hepatitis C Virus (HCV)-Induced Type II Mixed Cryoglobulinemia (MCII)
por: Sautto, Giuseppe, et al.
Publicado: (2012)

SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital
por: Ferrari, Davide, et al.
Publicado: (2022)

Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
por: Zhou, Xiaoying, et al.
Publicado: (2023)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Dual-Domain Reporter Approach for Multiplex Identification of Major SARS-CoV-2 Variants of Concern in a Microarray-Based Assay
por: Damin, Francesco, et al.
Publicado: (2023)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro
por: Clementi, Nicola, et al.
Publicado: (2021)

A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation
por: Mazzara, Pietro Giuseppe, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies
por: Sautto, Giuseppe, et al.
Publicado: (2013)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
por: Mungmunpuntipantip, Rujitika, et al.
Publicado: (2023)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design
por: Toh, Teck-Hock, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides
por: Castelli, Matteo, et al.
Publicado: (2013)

The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year
por: Zhang, Zheng, et al.
Publicado: (2022)

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
por: Liang, Huang, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

A closer look at prion strains: Characterization and important implications
por: Solforosi, Laura, et al.
Publicado: (2013)

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections
por: Sautto, Giuseppe, et al.
Publicado: (2013)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing
por: Tong, Renyang, et al.
Publicado: (2023)

Differential Composition of Vaginal Microbiome, but Not of Seminal Microbiome, Is Associated With Successful Intrauterine Insemination in Couples With Idiopathic Infertility: A Prospective Observational Study
por: Amato, Virginia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3v6su0r496ejnrl2k1lt8chdbn